FAKTOR-OPTIONSSCHEIN - MODERNA | Real-time Bid/Ask 09:40:52 2024-07-04 EDT | ||
| 0.44 EUR / 0.45 EUR | +1.14% |
|
| Current month | -4.35% | ||
| 1 month | -39.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 0.44 | 0.00% |
| 24-07-03 | 0.44 | -2.22% |
| 24-07-02 | 0.45 | +2.27% |
| 24-07-01 | 0.44 | -4.35% |
| 24-06-28 | 0.46 | -6.12% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 09:32 am
More quotesStatic data
| Product type | Produits Exotiques |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MA81UV |
| ISIN | DE000MA81UV4 |
| Date issued | 2021-07-19 |
| Strike | 57.99 $ |
| Maturity | Unlimited |
| Parity | 122.38 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 29.51 € |
|---|---|
| Lowest since issue | 0.178 € |
| Spread | 0.01 € |
| Spread % | 2.22% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Certificates
- Certificat
